Latest News

13 February 2020

Catapult invests in Biohabit through the GM&C Life Sciences Fund

Catapult has completed a seed investment into Alderley Park based Biohabit through the Greater Manchester and Cheshire Life Sciences Fund.

Biohabit are developing a salivary test for the diagnosis of heart failure, which hopes to replace the need for existing blood tests.  By developing a test that is readily available in multiple healthcare settings, the company are aiming to reduce the time to diagnosis and reducing the costs involved for healthcare services. This has the added benefit of being able to better triage care for patients at the earliest available opportunity and better monitor disease progression.

Cardiovascular diseases are on the rise and heart failure is an ever-increasing problem in our ageing population; by reducing the barriers to disease diagnosis, Biohabit will be able to both serve this market, and open up new avenues for self-care and closer patient management.

This funding will enable them to run a a trial and continue to develop their product.

From our portfolio

Acea Health

Digital Healthcare Technology

Acea Health is a digital healthcare company developing an application called Flynotes - a new dig...

viewview our portfolio

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email